Timing of cochlear implantation in large vestibular aqueduct syndrome-a retrospective cohort analysis.

IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY
Frontiers in Neurology Pub Date : 2025-03-21 eCollection Date: 2025-01-01 DOI:10.3389/fneur.2025.1562198
Xiao Liu, Wanting Huang, Yunxiu Wang, Jingjing Xu, Lulu Xie, Lin Liu, Jia Chen
{"title":"Timing of cochlear implantation in large vestibular aqueduct syndrome-a retrospective cohort analysis.","authors":"Xiao Liu, Wanting Huang, Yunxiu Wang, Jingjing Xu, Lulu Xie, Lin Liu, Jia Chen","doi":"10.3389/fneur.2025.1562198","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Large vestibular aqueduct syndrome (LVAS) typically manifests fluctuating, progressive, or sudden hearing loss. Cochlear implantation (CI) is a critical intervention for LVAS patients when hearing aids (HA) no longer confer sufficient benefit. However, determining the optimal timing for CI remains challenging due to the heterogeneous and unpredictable nature of hearing loss progression, particularly when audiological criteria for CI are met, and HA can still provide benefits. This study aimed to address these complexities by analyzing real-world data on the timing of CI and clinical decision-making processes in pediatric LVAS patients.</p><p><strong>Methods: </strong>This retrospective cohort study reviewed the medical records of 74 pediatric patients (<18 years) with LVAS who underwent CI at a tertiary care hospital in China between 2010 and 2023. Clinical data, including newborn hearing screening (NBHS) results, methods of hearing loss identification, hearing levels at the initial audiological assessment (IAA), and patterns of hearing loss progression, were analyzed. Additionally, key milestones were evaluated, including age at hearing loss identification, IAA, and CI, and the durations between these events.</p><p><strong>Results: </strong>The median age at CI was 4.9 years (IQR: 3.0-6.8), with a median duration from IAA to CI of 2.9 years (IQR: 1.6-5.2). Patients identified through NBHS underwent CI earlier than those identified through poor response to sound or language learning difficulties. Moreover, patients with poor performance at IAA had an earlier age at CI and shorter duration from IAA to CI. CI timing was comparable among different hearing loss progression patterns. Finally, among patients meeting CI criteria but still benefiting from HA, while those who directly underwent CI had an earlier age at implantation, their interval from IAA to CI was similar to those who initially underwent HA fitting.</p><p><strong>Conclusion: </strong>The majority of LVAS patients experience progressive hearing loss and undergo CI during early childhood. Failure of NBHS and poor auditory performance at IAA are indicative of rapid hearing deterioration. Once audiological criteria for CI are met, prolonged observation appears unnecessary. Nevertheless, further prospective longitudinal studies are warranted to refine the timing and decision-making process.</p>","PeriodicalId":12575,"journal":{"name":"Frontiers in Neurology","volume":"16 ","pages":"1562198"},"PeriodicalIF":2.7000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968381/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fneur.2025.1562198","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Large vestibular aqueduct syndrome (LVAS) typically manifests fluctuating, progressive, or sudden hearing loss. Cochlear implantation (CI) is a critical intervention for LVAS patients when hearing aids (HA) no longer confer sufficient benefit. However, determining the optimal timing for CI remains challenging due to the heterogeneous and unpredictable nature of hearing loss progression, particularly when audiological criteria for CI are met, and HA can still provide benefits. This study aimed to address these complexities by analyzing real-world data on the timing of CI and clinical decision-making processes in pediatric LVAS patients.

Methods: This retrospective cohort study reviewed the medical records of 74 pediatric patients (<18 years) with LVAS who underwent CI at a tertiary care hospital in China between 2010 and 2023. Clinical data, including newborn hearing screening (NBHS) results, methods of hearing loss identification, hearing levels at the initial audiological assessment (IAA), and patterns of hearing loss progression, were analyzed. Additionally, key milestones were evaluated, including age at hearing loss identification, IAA, and CI, and the durations between these events.

Results: The median age at CI was 4.9 years (IQR: 3.0-6.8), with a median duration from IAA to CI of 2.9 years (IQR: 1.6-5.2). Patients identified through NBHS underwent CI earlier than those identified through poor response to sound or language learning difficulties. Moreover, patients with poor performance at IAA had an earlier age at CI and shorter duration from IAA to CI. CI timing was comparable among different hearing loss progression patterns. Finally, among patients meeting CI criteria but still benefiting from HA, while those who directly underwent CI had an earlier age at implantation, their interval from IAA to CI was similar to those who initially underwent HA fitting.

Conclusion: The majority of LVAS patients experience progressive hearing loss and undergo CI during early childhood. Failure of NBHS and poor auditory performance at IAA are indicative of rapid hearing deterioration. Once audiological criteria for CI are met, prolonged observation appears unnecessary. Nevertheless, further prospective longitudinal studies are warranted to refine the timing and decision-making process.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Neurology
Frontiers in Neurology CLINICAL NEUROLOGYNEUROSCIENCES -NEUROSCIENCES
CiteScore
4.90
自引率
8.80%
发文量
2792
审稿时长
14 weeks
期刊介绍: The section Stroke aims to quickly and accurately publish important experimental, translational and clinical studies, and reviews that contribute to the knowledge of stroke, its causes, manifestations, diagnosis, and management.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信